
North America Organoids Market Report (2021-2031) by Scope, Segmentation, Dynamics, and Competitive Analysis
No. of Pages: 187 | Report Code: TIPRE00018845 | Category: Life Sciences
No. of Pages: 187 | Report Code: TIPRE00018845 | Category: Life Sciences
The North America organoids market size is expected to reach US$ 6,574.44 million by 2031 from US$ 1,357.19 million in 2023. The market is estimated to record a CAGR of 21.8% from 2023 to 2031.
The North America organoids market is segmented into the US, Canada, and Mexico. In 2023, the US held the largest share of the organoids market in North America. The mounting number of patients suffering from chronic conditions and viral diseases, commercialization of organoid models, increasing activities in research and development, and innovations in stem cell research are a few factors propelling the organoids market. In addition, the rising grants and funding for organoid development contribute to the market growth.
North America Organoids Market Strategic Insights
North America Organoids Market Segmentation Analysis
Key segments that contributed to the derivation of the North America organoids market analysis are type, application, source, offering, and method.
Technological advancements enabling the combination of organoids with organ-on-a-chip facilitate various applications in biological and biomedical fields for disease modeling and clinical drug screening. Organoids and organ-on-a-chip, which serve as evolving pathological and human physiological in vitro models, have the potential to revolutionize the conventional paradigm of cancer research and produce real clinical benefits. The recent inclination in the collaborative application of organoids with organ-on-a-chip and 3D bioprinting enables the development of sophisticated cancer models to study underlying mechanisms of tumor-stroma interactions, multiorgan tumor metastasis, and cancer-microenvironment interactions. Organoid-on-a-chip, the incorporation of multiple organoids on a chip, exhibits the benefits of both organoid and organ-on-a-chip as well as provides a valuable tool to study multiorgan tumor metastases and cancer-microenvironment interactions.
Technological advancements have enabled the development of brain organoids-on-chip, liver organoids-on-chip, intestine organoids-on-chip, and more. Organoid-on-a-chip is an emerging segment with much scope for improvement. Thus, with cooperative efforts from interdisciplinary researchers to reach the full utility of organoids in human biomedical studies, the combination of organoids and organ-on-a-chip is emerging as a significant trend in the organoids market.
Based on country, the North America organoids market comprises the US, Canada, and Mexico. The US held the largest share in 2023.
Organoids have the potential to overcome several previous limitations in biomedical research aimed at gaining mechanistic insights into human development, producing accurate models of human disease, and generating patient-matched tissue sources for regenerative medicine. In 2023, researchers at the Wyss Institute at Harvard University and Duke University collaborated with Gameto to develop a human ovarian organoid that supports egg cell maturation and leads to new treatments for conditions such as infertility and ovarian cancer. The technology was licensed to Gameto in 2022 and is being used to develop therapeutics for diseases associated with the female reproductive system. Moreover, the US witnessed a rise in research activities on organoids. For instance, the Center for Stem Cell and Organoid Medicine (CuSTOM) at Cincinnati Children's is advancing personalized regenerative therapies using innovative stem cell technologies and organoids. The goal of the research is to engineer patient-specific, organoid-derived tissues for therapeutic transplantation. Thus, owing to the increasing research and development activities, rising demand for tissue engineering and organ transplantation, and high adoption rate of organoids, the demand for organoids is expected to grow in the US during the forecast period.
North America Organoids Market Report Highlights
Report Attribute
Details
Market size in 2023
US$ 1,357.19 Million
Market Size by 2031
US$ 6,574.44 Million
Global CAGR (2023 - 2031)
21.8%
Historical Data
2021-2022
Forecast period
2024-2031
Segments Covered
By Type
By Application
By Source
By Offering
Regions and Countries Covered
North America
Market leaders and key company profiles
North America Organoids Market Company Profiles
Some of the key players operating in the market STEMCELL Technologies Inc; Molecular Devices, LLC.; Hubrecht Organoid Technology; Definigen; Organoid Therapeutics; Thermo Fisher Scientific Inc; Corning Inc; Merck KGaA; InSphero; ACRO Biosystems; Bio-Techne Corp; SUN bioscience SA; ORGANOID SCIENCES Co., Ltd.; Crown Bioscience Inc; Sartorius AG; 3D Biotek LLC; Prellis Biologics Inc.; 3Dnamics Inc.; and Cellesce Ltd among others. These players are adopting various strategies such as expansion, product innovation, and mergers and acquisitions to provide innovative products to their consumers and increase their market share.
The following methodology has been followed for the collection and analysis of data presented in this report:
The research process begins with comprehensive secondary research, utilizing both internal and external sources to gather qualitative and quantitative data for each market. Commonly referenced secondary research sources include, but are not limited to:
Note: All financial data included in the Company Profiles section has been standardized to USD. For companies reporting in other currencies, figures have been converted to USD using the relevant exchange rates for the corresponding year.
The Insight Partners conducts a significant number of primary interviews each year with industry stakeholders and experts to validate its data analysis, and gain valuable insights. These research interviews are designed to:
Primary research is conducted via email interactions and telephone interviews, encompassing various markets, categories, segments, and sub-segments across different regions. Participants typically include:
The North America Organoids Market is valued at US$ 1,357.19 Million in 2023, it is projected to reach US$ 6,574.44 Million by 2031.
As per our report North America Organoids Market, the market size is valued at US$ 1,357.19 Million in 2023, projecting it to reach US$ 6,574.44 Million by 2031. This translates to a CAGR of approximately 21.8% during the forecast period.
The North America Organoids Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the North America Organoids Market report:
The North America Organoids Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The North America Organoids Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the North America Organoids Market value chain can benefit from the information contained in a comprehensive market report.